Revisiting the Gateway Drug Hypothesis for Cannabis: A Secondary Analysis of a Nationwide Survey Among Community Users in Japan
- PMID: 40590180
- PMCID: PMC12209865
- DOI: 10.1002/npr2.70033
Revisiting the Gateway Drug Hypothesis for Cannabis: A Secondary Analysis of a Nationwide Survey Among Community Users in Japan
Abstract
Aim: Cannabis has historically been used for medicinal and industrial purposes, but is strictly regulated worldwide due to the psychoactive effects of THC. In Japan, cannabis is frequently labeled a "gateway drug," yet strong causal evidence for progression to other substances is limited. This study investigates whether cannabis acts as a gateway drug among Japanese users.
Methods: An anonymous online survey was conducted in January 2021 with 3900 individuals reporting lifetime cannabis use in Japan. Participants were recruited via social media. The survey gathered data on demographics, cannabis and other substance use history, order of substance initiation, psychiatric background, and criminal records. A Sankey diagram visualized substance use progression, and odds ratios were calculated to assess the likelihood of using other substances following cannabis use.
Results: Of all respondents, 81.5% were male, with the largest age group being 20-24. Tobacco and alcohol were the most common initial substances, while cannabis was typically the third. Odds for subsequent use of alcohol, tobacco, methamphetamine, and other illicit drugs after cannabis use were 1.25, 0.77, 0.08, and 0.78, respectively, suggesting low probabilities of progression. Nearly half of those who reported cannabis as their third drug did not use other substances afterward.
Conclusion: Cannabis use in Japan typically follows alcohol and tobacco, and rarely leads to further drug use. These findings challenge the gateway hypothesis in the Japanese context. Shared vulnerabilities and strict drug policies may shape these patterns. Further research is warranted to explore the impact of legal changes on drug use behavior.
Registry and registration number of the study/trial: Not applicable.
Keywords: Japan; cannabis; gateway drug hypothesis; marijuana; substance use.
© 2025 The Author(s). Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures

Similar articles
-
Psychosocial interventions for cannabis use disorder.Cochrane Database Syst Rev. 2016 May 5;2016(5):CD005336. doi: 10.1002/14651858.CD005336.pub4. Cochrane Database Syst Rev. 2016. PMID: 27149547 Free PMC article.
-
Psychological therapies for post-traumatic stress disorder and comorbid substance use disorder.Cochrane Database Syst Rev. 2016 Apr 4;4(4):CD010204. doi: 10.1002/14651858.CD010204.pub2. Cochrane Database Syst Rev. 2016. PMID: 27040448 Free PMC article.
-
Surveillance for Violent Deaths - National Violent Death Reporting System, 50 States, the District of Columbia, and Puerto Rico, 2022.MMWR Surveill Summ. 2025 Jun 12;74(5):1-42. doi: 10.15585/mmwr.ss7405a1. MMWR Surveill Summ. 2025. PMID: 40493548 Free PMC article.
-
'In the weeds': navigating the complex concerns, challenges and choices associated with medicinal cannabis consumption for endometriosis.Reprod Fertil. 2025 Jun 12;6(2):e240098. doi: 10.1530/RAF-24-0098. Print 2025 Apr 1. Reprod Fertil. 2025. PMID: 40445778 Free PMC article.
-
Incentives for preventing smoking in children and adolescents.Cochrane Database Syst Rev. 2017 Jun 6;6(6):CD008645. doi: 10.1002/14651858.CD008645.pub3. Cochrane Database Syst Rev. 2017. PMID: 28585288 Free PMC article.
References
-
- Matthew T., Welling M. A., Deseo A. B., and Monika S. D., “Biosynthetic Origins of Unusual Cannabimimetic Phytocannabinoids in Cannabis Sativa L: A Review,” Phytochemistry 201 (2022): 113282. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials